Beneficial effects of fingolimod in MS patients with high serum Sema4A levels

We previously demonstrated that patients with multiple sclerosis (MS) of high serum Sema4A levels are resistant to IFN-β therapy. To further elucidate the role of serum Sema4A as a biomarker for therapeutic stratification in MS patients, it is important to clarify the efficacy of other disease-modif...

Descripción completa

Detalles Bibliográficos
Autores principales: Koda, Toru, Namba, Akiko, Nakatsuji, Yuji, Niino, Masaaki, Miyazaki, Yusei, Sugimoto, Tomoyuki, Kinoshita, Makoto, Takata, Kazushiro, Yamashita, Kazuya, Shimizu, Mikito, Fukazawa, Toshiyuki, Kumanogoh, Atsushi, Mochizuki, Hideki, Okuno, Tatsusada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843273/
https://www.ncbi.nlm.nih.gov/pubmed/29518148
http://dx.doi.org/10.1371/journal.pone.0193986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843273/
https://www.ncbi.nlm.nih.gov/pubmed/29518148
http://dx.doi.org/10.1371/journal.pone.0193986

Ejemplares similares